Madrigal Pharmaceuticals (MDGL) Asset Writedowns and Impairment (2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Asset Writedowns and Impairment of $10.4 million for Q2 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Asset Writedowns and Impairment (2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Asset Writedowns and Impairment for 1 consecutive years, with $10.4 million the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 15.76 Bn | 14.93 Bn | - |